COMPANY

Acera Surgical

Acera Surgical is a bioscience company developing and commercializing a portfolio of fully engineered materials for regenerative medicine. Acera’s electrospun fibers are sub-cellular in size and free of animal and human components. From company website Source · Oct 12, 2026

Keywords: Diabetic Foot Ulcer Surgical Wound Venous Leg Ulcer Wound Heal Synthetic Electrospun Fiber Matrix Restrata TM Wound Matrix Restrata

Profile checked Oct 10, 2026

5Trials (company is sponsor)1FDA records (2 yrs)

Timeline

Jun 20, 2025 FDA FDA 510(k) clearance: Restrata Soft Tissue Reinforcement (STR) — K251224, Jun 20, 2025. Applicant at approval: Acera Surgical, Inc. source ↗
Oct 31, 2024 Trial start —: A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms source ↗
Jul 19, 2021 Trial start Not phased (device or behavioral study): Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous source ↗
May 5, 2021 Trial start Not phased (device or behavioral study): Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers source ↗
Apr 9, 2021 Trial start Not phased (device or behavioral study): Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site source ↗
Sep 14, 2017 Trial start Not phased (device or behavioral study): Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU) source ↗

Upcoming milestones

2027-08 (ESTIMATED) · · A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms · NCT06578650

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT06578650	A Prospective, Single-arm, Clinical Trial of Electrospun Fiber Matrix (Restrata) in the Treatment of Surgical Defects Secondary to Resection of Malignant Cutaneous Neoplasms	Not listed	Recruiting	Oct 31, 2024	2027-08 (estimated)
NCT04927702	Assessment of Wound Closure Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers (DFU) and With Living Cellular Skin Substitute in Treating Venous Leg Ulcers (VLU)	Not phased (device or behavioral study)	Terminated	Jul 19, 2021	Jul 15, 2024 (actual)
NCT03312595	Clinical Outcomes After Treatment With RestrataTM Wound Matrix in Diabetic Foot Ulcers (DFU)	Not phased (device or behavioral study)	Completed	Sep 14, 2017	Jul 15, 2018 (actual)
NCT04918784	Comparing Synthetic Hybrid-Scale Fiber Matrix With Standard of Care in Treating Diabetic Foot Ulcers	Not phased (device or behavioral study)	Completed	May 5, 2021	Jul 31, 2022 (actual)
NCT04829331	Utility of Restrata With Split Thickness Skin Graft to Reconstruct the Forearm Donor Site	Not phased (device or behavioral study)	Terminated	Apr 9, 2021	Jan 1, 2022 (actual)

FDA records (last 2 years)

Jun 20, 2025 FDA 510(k) clearance: Restrata Soft Tissue Reinforcement (STR) — K251224, Jun 20, 2025. Applicant at approval: Acera Surgical, Inc. source ↗

Connect

See your connections at Acera Surgical on LinkedIn (search by name, results not checked)

LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.

LinkedIn page linked from the company's own site: source · seen 2026-10-12